Demographic characteristics of the 177 subjects
| Diagnostic group | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PD (n = 92) | P+ (n = 12) * | DLB (n = 5) | VP (n = 15) | Dystonia (n = 5) | DIP (n = 12) | ET (n = 16) | Psy (n = 20) | |||||||||
| *Parkinson+ group included four patients with progressive supranuclear palsy and eight with multiple system atrophy. | ||||||||||||||||
| DIP, drug induced parkinsonism; DLB, dementia with Lewy bodies; ET, essential tremor; F, female; M, male; n, number of cases; P+, Parkinson plus syndromes; PD, Parkinson’s disease; Psy, reference cases with psychogenic parkinsonism; VP, vascular parkinsonism; y, years. | ||||||||||||||||
| F/M (n) | 41/51 | 6/6 | 2/3 | 7/8 | 1/4 | 5/7 | 8/8 | 8/12 | ||||||||
| Mean age (y) | 59.4 | 65.4 | 69.0 | 70.7 | 51.0 | 62.6 | 53.9 | 53.1 | ||||||||
| Age range (y) | 31.8 to 78.8 | 54.6 to 77.4 | 55.1 to 76.9 | 48.5 to 82.1 | 38.1 to 66.7 | 43.8 to 84.2 | 35.1 to 74.3 | 29.2 to 77.8 | ||||||||
| Duration of symptoms (y) | 2.8 (2.8) | 4.5 (3.9) | 2.0 (0.7) | 2.1 (1.9) | 11.3 (13.0) | 7.0 (2.1) | 4.3 (5.0) | 4.9 (5.8) | ||||||||
| L-dopa | 31 (34%) | 5 (42%) | 1 (25%) | 4 (36%) | – | 1 (8%) | 2 (11%) | – | ||||||||
| Dopamine agonist | 6 (6.5%) | 1 (8%) | – | – | – | 1 (8%) | – | 1 (4.5%) | ||||||||
| Selegiline | 9 (11%) | 1 (8%) | – | – | – | – | – | 1 (4.5%) | ||||||||
| Anticholinergic | 3 (3%) | – | – | 1(7%) | – | 2 (17%) | – | – | ||||||||
| Amantadine | 5 (5.4%) | 1 (8%) | – | – | – | – | – | – | ||||||||